After treatment with ipilimumab in prostate cancer patients, the levels of VISTA+ TILs and macrophages were significantly upregulated, indicating that VISTA might contribute to acquired resistance to current ICB treatments, and the combined blockade of VISTA and CTLA-4 may exert better effects than blockade of either factor alone. This evidence concerns the gene VSIR and prostate cancer.